BioVie Aligns with FDA on Trial to Assess Bezisterim in Parkinson’s

 SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa

Company engaged in trial start-up activities and plans to initiate patient screening Q4 2024

https://www.globenewswire.com/news-release/2024/08/08/2926683/0/en/BioVie-Announces-Alignment-with-FDA-on-Clinical-Trial-to-Assess-Bezisterim-in-Parkinson-s-Disease.html